Nkarta Inc
NASDAQ:NKTX
Intrinsic Value
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. [ Read More ]
The intrinsic value of one NKTX stock under the Base Case scenario is 3.52 USD. Compared to the current market price of 6.82 USD, Nkarta Inc is Overvalued by 48%.
Valuation Backtest
Nkarta Inc
Run backtest to discover the historical profit from buying and selling NKTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Nkarta Inc
Current Assets | 253.1m |
Cash & Short-Term Investments | 248.2m |
Other Current Assets | 4.9m |
Non-Current Assets | 125.8m |
PP&E | 119.3m |
Other Non-Current Assets | 6.5m |
Current Liabilities | 23.3m |
Accounts Payable | 3.7m |
Accrued Liabilities | 18.8m |
Other Current Liabilities | 855k |
Non-Current Liabilities | 82.3m |
Other Non-Current Liabilities | 82.3m |
Earnings Waterfall
Nkarta Inc
Revenue
|
0
USD
|
Operating Expenses
|
-131.7m
USD
|
Operating Income
|
-131.7m
USD
|
Other Expenses
|
14.1m
USD
|
Net Income
|
-117.5m
USD
|
Free Cash Flow Analysis
Nkarta Inc
NKTX Profitability Score
Profitability Due Diligence
Nkarta Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Nkarta Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
NKTX Solvency Score
Solvency Due Diligence
Nkarta Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Nkarta Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NKTX Price Targets Summary
Nkarta Inc
According to Wall Street analysts, the average 1-year price target for NKTX is 19.64 USD with a low forecast of 15.15 USD and a high forecast of 26.25 USD.
Ownership
NKTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NKTX Price
Nkarta Inc
Average Annual Return | -36.72% |
Standard Deviation of Annual Returns | 53.51% |
Max Drawdown | -98% |
Market Capitalization | 480.3m USD |
Shares Outstanding | 70 426 200 |
Percentage of Shares Shorted | 8.69% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 136 full-time employees. The company went IPO on 2020-07-10. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety and a membrane-bound form of the cytokine IL15 (mbIL-15). The Company’s co-lead product candidates are NKX101 and NKX019. NKX101 is designed to innate NK biology to detect and kill cancerous cells. The primary activating receptor for NK cells is known as NKG2D, which works through the detection of stress ligands displayed by cancerous cells. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells for understanding NK cell biology.
Contact
IPO
Employees
Officers
The intrinsic value of one NKTX stock under the Base Case scenario is 3.52 USD.
Compared to the current market price of 6.82 USD, Nkarta Inc is Overvalued by 48%.